SavedAdd your journal

Journals / Viral Hepatitis Journal / 2021 / Cilt: 27 - Sayı: 3

Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children

Çocuklarda Kronik Hepatit B Enfeksiyonunda Tenofovir Disoproksil Fumarat Tedavisi

Asuman Nur KARHAN
Ersin GÜMÜŞ
Hayriye HIZARCIOĞLU GÜLŞEN
Hülya DEMİR
İnci Nur SALTIK
Pages
142–147
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: All patients were positive for hepatitis B e antigen (HBeAg) at baseline.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aim of this study was to present real-world data regarding the efficacy and safety of tenofovir disoproxil fumarate (TDF) in pediatric patients with chronic hepatitis B (CHB).
📊
Key Findings & Data:Materials and Methods: In this observational retrospective cohort study, medical records of 10 children with CHB receiving TDF were reviewed.
💡
Conclusion & Impact:Results: All patients were positive for hepatitis B e antigen (HBeAg) at baseline.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: The aim of this study was to present real-world data regarding the efficacy and safety of tenofovir disoproxil fumarate (TDF) in pediatric patients with chronic hepatitis B (CHB). Materials and Methods: In this observational retrospective cohort study, medical records of 10 children with CHB receiving TDF were reviewed. Results: All patients were positive for hepatitis B e antigen (HBeAg) at baseline. HBV-DNA

Özet

Amaç: Bu çalışmanın amacı, pediatrik kronik hepatit B (KHB) tedavisinde tenofovir disoproksil fumaratın (TDF) etkinliği ve güvenliği ile ilgili verileri sunmaktır. Gereç ve Yöntemler: Bu gözlemsel retrospektif kohort çalışmasında, TDF tedavisi alan KHB enfeksiyonu olan 10 çocuğun tıbbi kayıtları geriye dönük olarak incelendi. Bulgular: Tedavi başlangıcında tüm hastalarda hepatit B e antijen (HBeAg) pozitifti. Son poliklinik kontrolünde, hastaların %70’inde HBV-DNA

🔖

Cite This Article

KARHAN, A. N., GÜMÜŞ, E., GÜLŞEN, H. H., DEMİR, H., SALTIK, İ. N. (2022). Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children. Viral Hepatitis Journal, Cilt: 27 - Sayı: 3, 142–147. https://ajindex.com/articles/646328

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212-2219
  2. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. [World Health Organisation web site]. March 2015.: Available at: http://www.who.int/hiv/pub/hepatitis/ hepatitis-b-guidelines/en/ 3. Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology. 1995;22:1387-1392
  3. Komatsu H, Inui A, Fujisawa T. Pediatric hepatitis B treatment. Ann Transl Med. 2017;5:37
  4. Murray KF, Szenborn L, Wysocki J, Rossi S, Corsa AC, Dinh P, McHutchison J, Pang PS, Luminos LM, Pawlowska M, Mizerski J. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology. 2012;56:2018-2026
  5. Evaluating the efficacy, safety and tolerability of tenofovir df in pediatric patients with chronic hepatitis B infection. ClinicalTrials. gov Identifier: NCT01651403 [U.S. National Library of Medicine ClinicalTrials.gov web site]. July 27, 2012.: Available at: https:// clinicaltrials.gov/ct2/show/NCT01651403 7. Choe JY, Ko JS, Choe BH, Kim JE, Kang B, Lee KJ, Yang HR. Antiviral efficacy of tenofovir monotherapy in children with nucleos(t)idenaive chronic hepatitis B. J Korean Med Sci. 2018;33:e11
  6. Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, Kelly D, Mieli-Vergani G; European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Hepatol. 2013;59:814- 829
  7. Wang HL, Lu X, Yang X, Xu N. Antiviral therapy in lamivudine-resistant chronic hepatitis b patients: a systematic review and network metaanalysis. Gastroenterol Res Pract. 2016;2016:3435965
  8. Kocak N, Ozen H, Saltik IN, Gürakan F, Yüce A. Lamivudine for children with chronic hepatitis B. Am J Gastroenterol. 2000;95:2989- 2990
  9. Kocak N, Saltik IN, Ozen H, Yüce, Gürakan F. Lamivudine treatment for children with interferon refractory chronic hepatitis B. Hepatology. 2000;31:545
  10. Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Li